Global Opioid Induced Constipation Treatment Market: Overview 

Opioids are medicines that function as pain killers and medications for medical conditions such as diarrhea and coughing, if they are used to a certain extent. Consumption of these medicines in patients is also responsible for constipation. Several medicines are being tested to increase worldwide demand for induced opioid constipation therapy in order to treat these diseases. The amount of opioid-induced constipation patients worldwide is growing. According to the American Academy of Pain Medicine, nearly 100 mn US patients were suffering from OIC in 2013. They added that the amount of individuals taking opioid medicine is anticipated to rise. The increasing demand for opioid-induced constipating treatment is expected to increase more in OIC patients, especially in North America. 

In the medical field, the constipation induced by opioid consumption is not yet adequately supplemented in a stable way. However, the rise of pipeline approval is expected to work worldwide in favor of a market for opioid-induced constipation therapy. 

By the end of 2016, the global opioid-induced constipation treatment market was estimated at US$ 731.2 million. This is anticipated to achieve US$ 4.8 billion by 2023 due to a whopping CAGR of 31.2 percent from 2015 to 2023. 

Chloride Channel Activators to Lose Traction to Mu-opioid Receptor Antagonists 

The most common type of opioid-induced constipation treatment medication is projected to be chloride canal activators by the end of 2016. This trend will proceed in the next few years, but the leading role in the medication classes will be forecast to be mu-opioid receptor antagonists. The surge in amount of Amitiza sales since it was approved in 2013 and specifically used for the opioid-based constipation therapy is one important reason for the popularity of chloride channel activators. 

Over time it is anticipated that the increasing amount of antagonistic mu-opioid recipients will lead to an increasing degree of efficacy in relation to the other drug classes by 2023. The growing amount of prescriptions for the treatment of opioid caused constipation owing to innovations that decrease their side effects will also profit from this medical class. 

The most common threshold for opioid-induced drug therapy is however the lack of knowledge of opioid-induced constipation for patients, a lack of attention to future therapy development, elevated costs for new drugstores and unfavorable refund rules by medical coverage organizations. However, there are currently a number of opioid-induced constipation pipeline medicines available. The approval of these medicinal products will support the development of this presently mainly untapped market. 

Global Opioid Induced Constipation Treatment Market: Regional Outlook 

The global opioid-induced constipation treatment market has been segmented geographicalaly into North America, Latin America, Asia Pacific, the Middle East and South Africa, and Europe. A significant portion of worldwide opioid-induced constipation treatment has been used in North America always. North America alone will produce 4.05 billion US dollars of worldwide income from opioid constipation treatment by the end of 2023. It also contributes to a growing demand level because of the big proportion of people who consume opioid medicines and suffer from the OIC. These results are obtained from a large amount of patients with chronic diseases and opioid use. 

Global Opioid Induced Constipation Treatment Market: Companies Mentioned 

Key vendors operating in the global opioid-induced constipation treatment market are Abbott Laboratories, C.B. Fleet Company, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Daewoong Co. Ltd., Cosmo Pharmaceuticals, and Boehringer Ingelheim. 

The industry seems to be fragmented and the competitive climate is quite intense with the presence of various businesses.

This report on the opioid induced constipation treatment market studies the current and future scenario of the global market. Large number of chronic pain sufferers is responsible for rising opioid consumption. Severe chronic constipation is a major side effect of consumption of opioid and shows resistance to traditional laxatives. Hence, novel targeted therapy has been prescribed to treat opioid induced constipation. Rising number of OIC sufferers, launch of targeted medicines, and growing awareness about the therapy are the major drivers of the market. 

The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market. 

Based on dosage form of the drug, the market has been segmented into three major forms: solid, semi-solid, and liquid. The market segments have been analyzed based on available approved drugs for treatment and their dosage forms, cost-effectiveness, and preference for dosage form by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Based on drug class, the opioid induced constipation treatment market has been segmented into three major categories based on their mechanism of action: mu opioid receptor antagonist (Movantik and Relistor), chloride channel activator (Amitiza), and others (Resolor and traditional medicines). The market segments have been extensively analyzed based on efficacy, cost, revenue, number of launched drugs, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Pipeline analysis has also been provided in the report. The market has been estimated for drugs that are in phase III (late stage) clinical trials. Presently, Naldemedine is an under NDA review. A tabular representation has been included for phase II and phase I drugs. 

Geographically, the global opioid induced constipation treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia Pacific (Australia, Japan, South Korea, and Rest of Asia Pacific), Latin America (Brazil and Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. 

The report also profiles major players in the global opioid induced constipation treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. 

The global opioid induced constipation treatment market has been segmented as follows:

  • Global Opioid Induced Constipation Treatment Market Revenue, by Dosage form of Drugs, 2013–2023 (US$ Mn)
    • Solid
    • Semisolid
    • Liquid
  • Global Opioid Induced Constipation Treatment Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
    • mu-opioid receptor antagonist
    • Chloride channel activator
    • Others
  • Global Opioid Induced Constipation Treatment Market Revenue, by Pipeline, 2013–2023 (US$ Mn)
    • Late Stage (phase III) candidates (forecast from the year of approval till 2023) (US$ Mn)
      • Naldemedine
      • Others
    • Early Stage (phase II and phase I) candidates (tabular representation)
      • Axelopran
      • Others
  • Global Opioid Induced Constipation Treatment Market Revenue, By Geography, 2013–2023 (US$ Mn)
    • Overview
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia Pacific
      • Australia
      • Japan
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Rest of the World